Quantcast

Industry news that matters to you.  Learn more

Archives for November 2012

New Hope for Understanding Autism Spectrum Disorders

Researchers from McGill University and the University of Montreal have identified a crucial link between protein synthesis and autism spectrum disorders (ASD), which can bolster new therapeutic avenues. Regulation of protein synthesis, also termed mRNA translation, is the process by which cells manufacture proteins. This mechanism is involved in all aspects of cell and organism function. A new study in mice has found that abnormally high synthesis of a group of neuronal proteins called neuroligins results in symptoms similar to those diagnosed in ASD. The study also reveals that autism-like behaviors can be rectified in adult mice with compounds inhibiting protein synthesis, or with gene-therapy targeting neuroligins. Their results are published in the journal Nature.

Mesothelioma Drug Slows Disease Progression in Patients with an Inactive NF2 Gene

Preliminary findings from the first trial of a new drug for patients with mesothelioma show that it has some success in preventing the spread of the deadly disease in patients lacking an active tumour suppressor gene called NF2. The study is presented at the 24th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Friday) [2].

GNS Healthcare, Dana-Farber and Mount Sinai Collaborate to Build Computer Model of Multiple Myeloma

GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute (Dana-Farber) and Mount Sinai School of Medicine (Mount Sinai) to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S. that constitutes approximately one percent of all cancers. Created using GNS’s supercomputer-driven REFS™ (Reverse Engineering and Forward Simulation) platform, the models will be used to help researchers discover novel therapies for the disease and to help determine the best existing treatments for patients.

Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone

Arno Therapeutics, Inc. (OTCBB: ARNI) recently reported progress in its clinical biomarker program to develop a companion diagnostic with onapristone in the treatment of breast and other cancers. Onapristone is the company’s investigational progestin receptor antagonist that has demonstrated anti-tumor activity in preclinical and clinical studies of hormone-dependent tumors.

Text Mining: Technology to Speed Up Alzheimer’s Biomarker Discovery

New research proves that ‘text mining’ or using the power of computers to read the entire biomedical knowledge base, is a promising new tool in the search for Alzheimer’s disease biomarkers.
The research, led by King’s College London’s Institute of Psychiatry and published in BioMed Central’s open access journal, the Journal of Translational Medicine, is the first to use this technology on such a large scale to look for potential biomarkers for disease.